This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-24 and is reviewed periodically as new material appears.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Friedrich Wöhler discovered that an organic substance, urea, could be produced from inorganic starting materials in 1828. That was an important conceptual milestone in chemistry by being the first example of a synthesis of a substance that had been known only as a byproduct of living processes. Wöhler obtained urea by treating silver cyanate with ammonium chloride, a simple, one-step synthesis:
Codeine became a prescription-only medication in the province of Manitoba on 1 February 2016. The number of low-dose codeine tablets sold in Manitoba decreased by 94 percent from 52.5 million tablets sold in the year prior to the policy change to 3.3 million in the year after. A pharmacist may issue a prescription, and all purchases are logged to a central database to prevent overprescribing. Saskatchewan's pharmacy college is considering enacting a similar ban to Manitoba's. On 9 May 2019, the Canadian Pharmacists Association wrote to Health Canada proposing regulations amending the NCR, the BOTSR, and the FDR - Part G, which included requiring that all products containing codeine be available by prescription only. New safety measures were issued by Health Canada on 28 July 2016; "codeine should no longer be used (contraindicated) in patients under 18 years of age to treat pain after surgery to remove tonsils or adenoids, as these patients are more susceptible to the risk of serious breathing problems. Codeine (prescription and non-prescription) is already not recommended for children under the age of 12, for any use."
== Pharmacology == Coronaridine has been reported to bind to an assortment of molecular sites, including: μ-opioid (Ki = 2.0 μM), δ-opioid (Ki = 8.1 μM), and κ-opioid receptors (Ki = 4.3 μM), NMDA receptor (Ki = 6.24 μM) (as an antagonist), and nAChRs (as an antagonist). It has also been found to inhibit the enzyme acetylcholinesterase, act as a voltage-gated sodium channel blocker, and displays estrogenic activity in rodents. In contrast to ibogaine and other iboga alkaloids, coronaridine does not bind to either the σ1 or σ2 receptor.
Improving metabolism (improving insulin sensitivity, inhibiting de novo lipogenesis, or increasing fatty acid oxidation). Metabolic modulators tested in MASH include glucagon-like peptide-1 receptor agonists (GLP-1 agonists), GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) or glucagon co-agonists and thyromimetics. Some of these drugs may treat MASFLD by significantly reducing body weight. Reducing inflammation, for example reducing oxidative stress and hepatocyte death. These drugs, such as chemokine antagonists, anti-apoptotics, vascular adhesion protein-1 inhibitors, and c-Jun N-terminal kinase inhibitors, have not shown benefit. "Gut-liver axis targets" that either change a person's microbiome, or act on bile acids Anti-fibrotic drugs, such as fibroblast growth factor analogues, which have largely not met their endpoints Other treatments such as farnesoid X receptor (FXR) agonists, peroxisome proliferator-activated receptor (PPAR) agonists, and ASK1 (apoptosis signal-regulating kinase 1) inhibitors may improve MASFLD by multiple mechanisms simultaneously.
Sources: en.wikipedia.org
In response to the presence of Navy warships in Latin America, two Venezuelan BMA F-16 fighter jets flew over the USS Jason Dunham on 4 September. The US Department of Defense called it "highly provocative" and deployed ten F-35 fighter jets and two MQ-9 Reaper drones to Puerto Rico. That same day Marco Rubio, the US Secretary of State, met with President of Ecuador Daniel Noboa in Quito; Rubio stated that Trump intended to "wage war" on those that have "been waging war on us for 30 years" and designated the gangs Los Lobos and Los Choneros as narco terrorists, with Noboa's agreement. On 23 September, the United States added the 18th Street gang, which is largely based in the Caribbean coastal nations of Guatemala and Honduras, to the designated foreign terrorists list. The Venezuelan government stated on 12 September that a US destroyer had detained and boarded a tuna fishing boat with nine crew members. The destroyer eventually released the boat, and it was escorted away by the Venezuelan Navy. Minister of Foreign Affairs Yván Gil described the act as illegal and said that Venezuela would defend itself.
A microprotein (miP) is a small protein of about 100–150 amino acids or fewer encoded from a small open reading frame (sORF), also known as sORF-encoded protein (SEP). They are a class of protein with a single protein domain. They are related to multidomain proteins. Microproteins regulate larger multidomain proteins at the post-translational level. Microproteins are analogous to microRNAs (miRNAs) and heterodimerize with their targets causing dominant and negative effects. In animals and plants, microproteins influence many biological processes. Because of their dominant effects on their targets, microproteins are currently under study for use in biotechnology. There are several methods for microprotein study, such as ribosome profiling, mass spectrometry, and genetic screening. In humans, they are associated with genetic diseases and cancers, and are called peptideins.
=== Detection === Modafinil is considered a stimulant doping agent and as such is prohibited by World Anti-Doping Agency in sports competitions. Modafinil enantiomers can be separately quantified in biological samples.
2 March – Bertie O'Brien, 71, Gaelic footballer and hurler (St. Finbarr's, Cork senior teams). 3 March Camille Souter, 93, artist. Rita O'Hare, 80, Republican activist. 5 March – Maurice Scully, 70, poet. 10 March – Niall Brophy, 87, rugby union player (Leinster, national team, Lions). 12 March – Liam Kearns, 61, Gaelic footballer (Austin Stacks, Kerry senior team) and manager (Limerick, Laois, Tipperary, Offaly). 13 March – Tom Ryan, 81, hurler (Killenaule, Éire Óg, James Stephens, Tipperary senior team). 22 March – Marcus Wilson, 91, Gaelic footballer (St. Vincent's, Dublin senior teams). 25 March – Ger Glavin, 66, hurler (Midleton) and Gaelic footballer (Ballincollig, Imokilly, Cork senior team). 28 March – Jimmy Gray, 93, Gaelic footballer and hurler (Na Fianna, Dublin senior teams). 31 March – Harry Cassidy, 92, Gaelic footballer and manager (Bellaghy, Derry senior team). Born in Northern Ireland.
both patentable and otherwise, should be shared 'without fee or stipulation'", or, given the "[difference] between patenting for personal gain and patenting in the public interest" whether "a new process or discovery [should be patented] in the public interest" — the medical profession had a further concern. The term, "patented medicine" strongly suggested the unscientific, testimonial-promoted, "cure all" preparation of the charlatan, quack, or snake oil salesman, universally known as a patent medicine. In 1911, the "free use" of more than 90% of the 250 patents that had been issued by the Patent Office to government employees had been given over, by those patentees, to "the government and the people of the United States". Given that, if the invention was "of any value", and the employee had not patented it, "there is the chance at any time that somebody else may take out the patent and collect royalties from the public", patenting was "for the protection of the public rather than for the protection of the patentee" and, in doing so, also "prevent[ed] some more mercenary individual from collecting royalties". In 1907, Frederick Cottrell, a colleague of Robertson's at the University of California, patented his electrostatic precipitator, designed to produce cleaner industrial chimney emissions (FC.1), and offered the rights to the University. From their view that the university's Charter precluded any commercial activity, the Regents of the University of California declined Cottrell's offer.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.